Concert Pharmaceuticals Announces Proposed Public Offering of Common Stock

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has commenced an underwritten public offering of its common stock. All of the shares in the offering are to be sold by Concert. Wells Fargo and JMP Securities are acting as joint book-running managers for the proposed offering. Concert intends to grant the underwriters... more →
Posted in: Press

Concert Pharmaceuticals Appoints James V. Cassella as Chief Development Officer

Concert Pharmaceuticals, Inc. (CNCE) today announced that it has appointed James V. Cassella, Ph.D. as Chief Development Officer. In this newly created role, Dr. Cassella will lead Concert’s product development strategy and operations and will have responsibility for all preclinical, clinical and manufacturing activities. “Jim... more →
Posted in: Press

Concert Pharmaceuticals to Be Added to NASDAQ Biotechnology Index

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ: NBI) effective prior to the market open on Monday, December 22, 2014. The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ-listed securities that are classified... more →
Posted in: Press

GW Pharmaceuticals to Present at the 26th Annual Piper Jaffray Healthcare Conference

GW Pharmaceuticals plc (GWPH) (GWP.L) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that Justin Gover, GW’s Chief Executive Officer, is... more →
Posted in: Press